Table 1.

Clinical characteristics of participants.

Baseline characteristic	Responder (n = 30)	Non-responder (n = 30)	p-value
Age (year), mean ±SD	61.13 ± 4.96	62.13 ± 6.29	0.436
≥65, n (%)	7 (23.3%)	14 (46.7%)
< 65, n (%)	23 (76.7%)	16 (53.3%)
Sex, n (%)			0.781
Male	21 (70%)	20 (66.7%)
Female	9 (30%)	10 (33.3%)
Clinical stage, n (%)			0.828
I	2 (6.7%)	1 (3.3%)
II	0	0
III	17 (56.7%)	17 (56.7%)
IV	11 (36.7%)	12 (40%)
Smoking history, n (%)			0.796
Yes	15 (50%)	16 (53.3%)
No	15 (50%)	14 (46.7%)
Pathological type, n (%)			0.666
SCLC	10 (33.3%)	11 (36.7%)
NSCLC
Squamous cell carcinoma	9 (30%)	6 (20%)
Adenocarcinoma	11 (36.7%)	13 (43.3%)
ECOG score, n (%)			0.554
0	1 (3.3%)	2 (6.7%)
1	29 (96.7%)	28 (93.3%)
Treatment			0.312
Chemotherapy	26	22
Targeted therapy	4	8

SD, standard deviation; ECOG, Eastern Cooperative Oncology Group.